NYSE:RCUS - New York Stock Exchange, Inc. - US03969F1093 - Common Stock - Currency: USD
RCUS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. Both the profitability and financial health of RCUS have multiple concerns. While showing a medium growth rate, RCUS is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -24.61% | ||
ROE | -58.35% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.1 | ||
Debt/FCF | N/A | ||
Altman-Z | -0.35 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.5 | ||
Quick Ratio | 4.5 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NYSE:RCUS (5/29/2025, 3:53:06 PM)
9.505
+0.38 (+4.11%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 3.9 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 2.08 | ||
P/tB | 2.08 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -24.61% | ||
ROE | -58.35% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.1 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 60% | ||
Cap/Sales | 2.33% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.5 | ||
Quick Ratio | 4.5 | ||
Altman-Z | -0.35 |